Use of risperidone long-acting injection to support treatment adherence and mood stabilization in pediatric bipolar patients: A case series

Journal of Clinical Psychiatry

Volumn 70, Issue 4, 2009, Pages 604-606

  Fu I, Lee ^a   Boarati, Miguel A ^a   Stravogiannis, Andreas ^a   Wang, Yuan Pang ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; FLUOXETINE; HALOPERIDOL; LITHIUM; LONG ACTING DRUG; LONG ACTING RISPERIDONE; METHYLPHENIDATE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ADOLESCENT; AGITATION; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CASE REPORT; CHILD; CLINICAL FEATURE; DEPRESSION; DRUG SAFETY; DRUG TREATMENT FAILURE; EUPHORIA; HUMAN; HYPERACTIVITY; HYPERENERGIZED; HYPERGLYCEMIA; LETTER; MAJOR DEPRESSION; MALE; MANIA; PHOBIA; PRIORITY JOURNAL; SCHOOL CHILD; SEDATION; SIDE EFFECT; SYMPTOM; TREATMENT REFUSAL; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHILD; DELAYED-ACTION PREPARATIONS; HUMANS; MALE; PATIENT COMPLIANCE; RISPERIDONE;

EID: 66349101038     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08l04487     Document Type: Letter

References (13)

1. Findling RL, McNamara NK. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 2004;65(suppl 6):30-44
2. DelBello MP, Hanseman D, Adler CM, et al. Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. Am J Psychiatry 2007;164(4):582-590 (Pubitemid 46650189)
3. Biederman J, Mick E, Wosniak J, et al. An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2005;15(2):311-317 (Pubitemid 40734110)
4. Bond DJ, Pratoomsri W, Yatham LN. Depot antipsychotic medications in bipolar disorder: a review of the literature. Acta Psychiatr Scand Suppl 2007;434:3-16 (Pubitemid 47231064)
5. Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr Scand Suppl 2007;434:50-56 (Pubitemid 47231068)
6. Marder SR, Conley R, Ereshefsky L, et al. Dosing and switching strategies for long-acting risperidone. J Clin Psychiatry 2003;64(suppl 16):41-46
7. Reich W, Welner Z, Herjanic B, et al. Diagnostic Interview for Children and Adolescents-IV (DICA-IV). North Tonawanda, NY: Multi-Health Systems; 1997
8. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Welfare, and Education publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
9. Shaffer D, Gould MS, Brasic J, et al. A Children's Global Assessment Scale. Arch Gen Psychiatry 1983;40:1228-1231
10. Pappagallo M, Silva R. The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol 2004;14(3):359-371 (Pubitemid 39473122)
11. Drotar D, Greenley RN, Demeter CA, et al. Adherence to pharmacological treatment for juvenile bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007;46(7):831-839 (Pubitemid 46975919)
12. Colom F, Vieta E, Tacchi MJ, et al. Identifying and improving nonadherence in bipolar disorders. Bipolar Disord 2005;7(suppl 5):24-31 (Pubitemid 43013457)
13. Coletti DJ, Leigh E, Gallelli KA, et al. Patterns of adherence to treatment in adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2005;15(6):913-917 (Pubitemid 43042982)